Reply to J. Edeline et al
- PMID: 35787066
- DOI: 10.1200/JCO.22.01283
Reply to J. Edeline et al
Conflict of interest statement
Comment on
-
Capecitabine: Still a Standard Option in the Adjuvant Setting of Biliary Tract Cancer?J Clin Oncol. 2022 Nov 1;40(31):3667-3668. doi: 10.1200/JCO.22.01213. Epub 2022 Jul 5. J Clin Oncol. 2022. PMID: 35786978 No abstract available.
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources